Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) EV-to-EBIT : -0.18 (As of Jun. 22, 2024)

Cotinga Pharmaceuticals EV-to-EBIT Chart

Cotinga Pharmaceuticals Annual Data
	Trend	Apr10	Apr11	Apr12	Apr13	Apr14	Apr15	Apr16	Apr17	Apr18	Apr19
EV-to-EBIT		Get a 7-Day Free Trial					-7.08	-13.24	-8.81	-1.30	-0.71

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
EV-to-EBIT	Get a 7-Day Free Trial															-0.87	-0.71	-1.47	-1.39	-0.91

Competitive Comparison of Cotinga Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Cotinga Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cotinga Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's EV-to-EBIT falls into.

Cotinga Pharmaceuticals EV-to-EBIT Calculation

Cotinga Pharmaceuticals's EV-to-EBIT for today is calculated as:

Cotinga Pharmaceuticals's current Enterprise Value is $0.33 Mil.
Cotinga Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cotinga Pharmaceuticals  (OTCPK:COTQF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cotinga Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2020 is calculated as:

Cotinga Pharmaceuticals's Enterprise Value for the quarter that ended in Jan. 2020 was $1.86 Mil.
Cotinga Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.81 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cotinga Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description